
ããããå£ããããã§ç®ãèŠãããå»è ã®ã±ããžã§ããã¯ãã€ãšãã
å»è ã®èªåã¯ãè«æãèªãã§ã¯èªåã§è©ŠããŠã¿ãªããšæ°ãæžãŸãªãã
ããææãçæéã®ççºçãªéåã«ã€ããŠã®ç ç©¶ãç«ãŠç¶ãã«èªãã ãHIITãšããéæ®µãé§ãäžããéåãšãã
ããã§ãå»å±ã®é ã«48kgã®ã±ãã«ãã«ããã£ãã眮ããã誰ãåãããªãããå®å šã«éªéç©æ±ããããŠãããã ãã©ãèªåã¯ãããä»äºã®åéã«æ¯ãåããŠããã
ã±ãã«ãã«ãæ¯ããã³ã«æ¯ã匷ãçãåãã®ã§ãå£ãããã·ã¥ãïŒã·ã¥ãïŒããšé³ãåºããååã«ããªãããããæ²žããŠãªãïŒããšèãããããšããã£ãããã¿ãŸãããããããããªãã§ããèªåã®å£ã§ãã
éåžžéæ®µãå šåã§é§ãäžããã®ãæ¥èª²ã«ãããè«æãèªãã§æ°ã«ãªã£ããããæ¬åœã«æ¯æ¥ãã£ããããããèžãå Žã§ææå蚺ã®äžå£ãšããéã£ãŠãæ±ã ãã®èªåãããã£ãšäžŠãã å çæ¹ã®åãæ¯ãåãããŠééããŠãã£ãã誰ã«ãäœãèšãããªãã£ãã®ããäžçªæãã£ãã
ãããªèªåããã±ããžã§ããã¯ãã€ãšããã1ãæã ãæ¬æ°ã§ãã£ãããšããããäœéã¯èœã¡ããè ¹çãèŠãå§ãããããã§ããããŠãä»ã¯æ®éã«ç±³ãé£ã¹ãŠããã
å»è ãªã®ã«YouTuberãä¿¡ããŠãç³è³ªã1æ¥20gã«ãã
ã±ããžã§ããã¯ãå§ããã®ã¯ãåœæããã£ãŠããæµ·å€ã®ãã£ãããã¹ç³»YouTuberããå šå¡ã±ãã ã£ãããã ã
ãèèªããšãã«ã®ãŒã«å€ããäœãäœãã
ãç³è³ªã¯æ¯ã
ãã±ãã¢ããããŒã·ã§ã³ïŒé©å¿ïŒããã°é ãã¯ãªã¢ã«ãªãã
å»è ãªã®ã«å®å šã«åœ±é¿ãããŠãããèªåãªãã«è«æãèªãã ãçæã®æžéã§å¹æãåºãå ±åã¯ãããçå±ã¯éãæ°ãããããã£ãŠã¿ãã
ç³è³ªã1æ¥20g以äžã«ãããç±³ããã³ã麺ãæç©ãé£ã¹ãªããšæ±ºãããèã»éã»åµã»ããŒãºã»ãããã»èéèãããã«MCTãªã€ã«ãèªåã®é£äºã¯ãã ããããã®ãããã«éãããã
äž»é£ãå°ãæžããçšåºŠã®ç³è³ªå¶éãšã¯ãå¥ç©ã ãã±ãã¯äžè¬ã«ãç³è³ªã1æ¥50gæªæºãŸã§çµããã±ãã³äœãå¢ããç¶æ ãç®æãé£äºã ãèªåã¯ããã®äžã§ãå³ããæžãããŠãã¹âŸã
3æ¥ç®ãããããé ãåããªããªã£ãã倿¥ã§æ£è ããã®ååãããåºãŠããªããã«ã«ããæžãã¹ããŒããèœã¡ããããã¯å§ããçŽåŸã®äžæçãªäœèª¿äžè¯ã§ãæåã®å£ãè¶ããã°é ãåŽããŠããã
ããèªåã«èšãèããããYouTuberãããèšã£ãŠããããã
2é±éãéãããããããäœéãèœã¡å§ããããã¶ã1ãæã§5ã6kgãæ£ç¢ºãªæ°åã¯èŠããŠããªããèŠãç®ãçµããŠãè ¹çãèŠãå§ããã
ãããããããšèª¿åã«ä¹ã£ãŠãããšããã§ãåã©ãã«èšãããã
ããããå£ãããã
ããããé¢çœããããã£ãã°ã¬ãŒããã«ãŒãé£ã¹ãããããªããšèª€éåãããã±ããžã§ããã¯äžã ãããæç©ãªããŠé£ã¹ããªãã
ãã¶ããã±ãã³äœã®äžã€ã§ããã¢ã»ãã³ãé¢ä¿ããŠãããã±ãé£ã§åŒæ°ã®ã¢ã»ãã³ãå¢ããããšã¯ãç ç©¶ã§ã確ãããããŠãã²âŸã
å®¶ã§èšããããªããè·å Žã§ãåãã ã£ããããããªããã±ãã«ãã«ã§ã·ã¥ãã·ã¥ãèšã£ãŠããå£ããããã®èããããŠããå¯èœæ§ããããååãã¡ãæ¬åœã«ç³ãèš³ãªãã£ãã
ã±ãã«ã¯ãããšããããããããã
äœéãèœã¡ãã®ã¯ãèªåã²ãšãã®äœéšã«ãšã©ãŸããªãã
ä»ãããããŠèª¿ã¹ããšãç³å°¿ç ãäºå矀ã®äººã1幎é远ã£ãã©ã³ãã å詊éšããããã±ãé£ã®çŸ€ã¯ãç³è³ªãäžçåºŠã«æããŠã«ããªãŒãå¶éãã矀ãããäœéæžå°ãšè¡ç³ã®ææšã§ããHbA1cã®äœäžã倧ããã£ããç³å°¿ç ã®è¬ãæžããã人ããã±ãé£ã®çŸ€ã®ã»ããå€ãã£ã³âŸã
å¥ã®Keto-Med詊éšã§ã¯ãç³å°¿ç ãäºå矀ã®äººãã±ãé£ãšå°äžæµ·é£å¯ãã®é£äºã12é±éãã€è©ŠãããHbA1cã¯ã©ã¡ãã§ãæ¹åããé£äºã®éã«çµ±èšåŠçãªææå·®ã¯ãªãã£ããäžæ§èèªã¯ã±ãé£ã®ã»ããäžãã£ãäžæ¹ãLDLã¯ã±ãé£ã§äžãããå°äžæµ·é£å¯ãã§ã¯äžãã£ãŠããâŽâŸã
ã©ã³ãã å詊éš14æ¬ããŸãšããã¡ã¿è§£æããããäœéãå€ãã§ç³å°¿ç ã®ãã人ã§ã¯ãã±ãé£ã¯äœèèªé£ã«æ¯ã¹ãŠHbA1cãšã€ã³ã¹ãªã³æµææ§ã®ææšãäžãããäžæ§èèªãäžãã£ãŠHDLãäžãã£ãŠãããäœéã¯ãç³å°¿ç ã®æç¡ã«ãããããèœã¡ãŠãã¹¹âŸã
ãèèªããšãã«ã®ãŒã«å€ããäœãããåã§ã¯ãªããéåäžã«èèªãçããéãå¢ããããšã¯ãåœéã¹ããŒãæ é€åŠäŒã®èŠè§£ã§ãèªããããŠããããã ãããã§éåã®ããã©ãŒãã³ã¹ãäžããããã§ã¯ãªããç³è³ªã®å€ãé£äºãšæ¯ã¹ãŠåçãããããèœã¡ããšãããŠãã¹âŸã
ã±ãã§å€ããã®ã¯ãäœéã ãã§ã¯ãªããè¡ç³ãäžæ§èèªãã€ã³ã¹ãªã³æµææ§ãŸã§æ¹åãã詊éšãããã
ã©ããç³å°¿ç ãäºå矀ãäœéãå€ãã®äººã®çµæãäžå¿ãªã®ã§ãå¥åº·ãªçãã¬å¥œããåãã ãåŸããããã©ããã¯ããããªããã©ãææãªã®ã¯ç¢ºãã ã
è ¹çãèŠãå§ããé ãLDLã¯182ã«ãªã£ãŠãã
ã±ããå§ããåã®LDLã³ã¬ã¹ãããŒã«ã¯112mg/dLã ã£ãã
ã±ããå§ããŠ1ãæã»ã©ã§ãå¥åº·èšºæããã£ããLDLã¯182mg/dLã«ãªã£ãŠãããæ¥æ¬åè硬ååŠäŒã®åºæºã§ã¯ã140mg/dL以äžã§ãé«LDLã³ã¬ã¹ãããŒã«è¡çãã«å ¥ãâµâŸãå®å šã«åŒã£ãããæ°åã ã
ç³è³ªå¶éã§LDLã倧ããäžãã人ã¯ãããç©ããŠããŠäžæ§èèªãäœãHDLãé«ã人ã§LDLã倧ããäžãããã¿ãŒã³ã«ã¯ãããªãŒã³ãã¹ã»ãã€ããŒã¬ã¹ãã³ããŒïŒLMHRïŒããšããç ç©¶äžã®åŒã³åãã€ããŠããâ¶âŸãèªåã®182ã¯ããã®æ¡ä»¶ã®äžã€ã§ããLDL200以äžã«ã¯å±ããŠããªãããã ãäžæ§èèªã¯äœãHDLã¯é«ããäœèèªçãäœãã£ããæ°åã¯è¶³ããªããŠãã䌌ãç¶æ ã®ããã«æããã
ãããŠãApoBã73ãã110ã«äžãã£ãŠããããããäœãã倧äºã ã£ãã
ApoBã¯ãLDLãå«ããåè硬åã«é¢ããç²åã®æ°ãåæ ããæ€æ»ã ãLDLã®å€ã ãã§ã¯ãç²åã倧ãããªã£ãã®ããæ°ãå¢ããã®ãã¯åãããªããæ°ãå¢ãããã©ããã¯ãApoBã§åãããLDLãšApoBãé£ãéããšããå¿è¡ç®¡ã®ãªã¹ã¯ã¯äžè¬ã«ApoBã®ã»ããšãã察å¿ãã¹²âŸã
äžæ§èèªãäœãHDLãé«ã人ã®LDLã¯ãç²åã倧ãããªã£ãŠããã ãã§æ°ã¯å¢ããŠããªãããã説æãããããšããããèªåã®å Žåã¯ãç²åã®æ°ãã®ãã®ã1.5åã«ãªã£ãŠãããäœéãèœã¡ãŠãè ¹çãèŠããŠãäœèª¿ãããã£ããããã§ããåè硬åã«é¢ããç²åã¯å¢ããŠããã
ApoBãšããæ€æ»ã®èªã¿æ¹ã¯ããã¡ãã«æžããŠããã
å¥èšºã§LDLæ£åžžã ã£ã人ã»ã©ãäžåºŠApoBãæž¬ã£ãŠã»ããïŒç¡æïŒ
ä»èª¿ã¹çŽããŠããLMHRãšããåé¡ã ãã§é«ãLDLãç¡èŠããŠãããšã¯å€æã§ããªããLDLãé«ãã»ã©ããŸãé«ãç¶æ ãé·ãç¶ãã»ã©åè硬åã®ãªã¹ã¯ã¯äžããããã®é¢ä¿ã¯ãéºäŒåŠçç ç©¶ã远跡ç ç©¶ãæ²»çã®è©Šéšã§æ¯æãããŠããâ·âŸãäžæ¹ãLMHRã®é·æãªã¹ã¯ãã©ã®çšåºŠãã¯ããŸã ååã«åãã£ãŠããªãâžâŸâ¹âŸã
èªåããäœéãèœã¡ãããæ€æ»å€ã¯æ°ã«ããªããŠããããšã¯æããªããç³è³ªå¶éã§LDLãäžãã£ããšãã®ç ç©¶ãšã远å ã§ç¢ºããããæ€æ»ã¯ãå¥ã®èšäºã«ãŸãšããã
ç³è³ªå¶éã§LDLãäžãã£ãããäœã確ããããïŒç¡æïŒ
è ¹çã¯èŠããã®ã«ããã³ãã®ãã¬ãŒãã1ææžã£ã
ãã¬ãŒãã³ã°ã«ãé¿ããããã³ããã¬ã¹ã®ééãèœã¡ãŠããã¬ãŒãã1ææžã£ããèŠãç®ã ãä»äžãã£ãããªããã¿ããã ã£ãã
ã±ããã®ãã®ã®åœ±é¿ã ã£ãã®ããæžéãé£äºéã®å€åãé¢ä¿ããã®ããèªåã®äœéšã ãã§ã¯åããããªããåœéã¹ããŒãæ é€åŠäŒã®èŠè§£ã§ããæå€§çåãçãã¬ã«ããçåã®äŒžã³ã¯ãç³è³ªã®å€ãé£äºãšããããåçšåºŠãšãããŠãã¹âŸãã±ãã«ãããèšé²ãå¿ ãèœã¡ãããšãŸã§ã¯èšããªããèªåã«ã¯åããªãã£ãã
ã«ã¬ãŒã®æ¥ã«ãã«ãŒæãã§ããšèšãç¶ããŠãéçããã
åã©ããšåãé£äºãã§ããªããèªåã ãç±³ãé£ã¹ãªããå®¶æã§å€é£ããŠããèªåã ãã¡ãã¥ãŒã極端ã«éãããã
ã仿¥ã«ã¬ãŒã ããã£ãŠèšãããŠããèªåã¯ã«ãŒæãã§ãèã ãé£ã¹ããïŒããç¶ããŠããããéçãããã
å£ããããšèšãããåã©ããšåãé£åã§ãèªåã ãéããã®ãé£ã¹ãŠããã
ããããªãã®ããã«ãã£ãŠããã ã£ãã
ãã®åãã«çããããªããªã£ãæç¹ã§çµãã£ãã
å®¶æã®ååãåŸãŠã工倫ããªããç¶ããŠãã人ãããã ããããã èªåã«ã¯ãå®¶æãšåããã®ãé£ã¹ãããªãäžäŸ¿ãããLDLã®æ°åããéãã£ãã
倿¥ã§çµå¶è ããããäŒé£ãæ¥åŸ ã®è©±ãèããŠããŠããå³ããç³è³ªå¶éãç¶ããããšããŠã¶ã€ããã®ã¯ããã®å£ã ãšæãããå®¶ãåºã§äœãé£ã¹ããã¯ãèªåã²ãšãã§ã¯æ±ºããããªãã
ã±ããç¶ãããªããéäžã§äžåºŠã¯æ¡è¡ã
ã±ãã§äœéãè¡ç³ããããªã£ã詊éšã¯ãããç®çãæç ãç¶ãããããã«ãã£ãŠã¯ãå»åž«ãšçžè«ããŠæ€èšããé£äºã®äžã€ã«ãªã¹â°âŸã
ãã ãå§ããåããLDLãApoBãã©ã®ãããäžãããããæ£ç¢ºã«äºæž¬ããã®ã¯é£ããã以åã®å¥èšºçµæãããã°ãèªåã®112ãã182ã®ãããªå€åã«æ°ã¥ãããã±ããç¶ãããªããéäžã§äžåºŠã¯è¡æ¶²æ€æ»ã§ç¢ºãããŠã»ããã
LDLã倧ããäžãã£ã人ã¯ã以åã®çµæãšé£äºã®å€æŽç¹ãæã£ãŠããã®ãŸãŸç¶ããŠãããã䞻治å»ã«çžè«ããŠã»ãããè¬ã飲ãã§ãã人ã¯ããã®ææãšè¬ã®çš®é¡ãäŒããã
ç³å°¿ç ã»è çŸæ£ã»è質ç°åžžçã§æ²»çäžã®äººããåŠåš äžã»æä¹³äžã®äººãæé·æã®åã©ãã«ã¯ç¹ã«æ³šæãå¿ èŠã ãåã©ãã«ãå€§äººã®æžéã®äœéšããã®ãŸãŸåœãŠã¯ããããšã¯ã§ããªã¹â°âŸã
èªå·±å€æã§é£äºã倧ããå€ãããå ã«å»åž«ãžçžè«ããŠã»ããã
èªåã¯ããã±ãããããªããç©ããæ¹æ³ãšããŠã¯ããããã«å¹ãããããã§ããå®¶æãšåãé£åã§åããã®ãé£ã¹ãããã»ããéžãã ã
ä»ã¯æ®éã«ç±³ãé£ã¹ãŠããã
ãŸãšã
ã±ãã1ãæç¶ããŠãèªåã®äœéã¯ãã¶ã5ã6kgèœã¡ããç ç©¶ã§ããäœéãè¡ç³ãäžæ§èèªãæ¹åãã詊éšã¯ããã
LDLã¯ãã±ãéå§åã®112ãããçŽ1ãæåŸã«ã¯182mg/dLã«ãªã£ãŠãããç²åã®æ°ãåæ ããApoBãã73ãã110ã«äžãã£ãŠãããäœéã®å€åã ãã§ãé£äºãåããã¯æ±ºããããªãã
ãããçç±ãšããŠãã¡ã°ã倧ããã£ãã®ã¯ãå®¶æãšåããã®ãé£ã¹ãããªãããšã ã£ãã
ãããŸã§èªãã§ãã ãã£ãŠãããããšãããããŸããã
圹ã«ç«ã£ãããã¹ãããæŒããŠãããããšããã¡ããã¡ãå±ã¿ã«ãªããŸããããããã®èšäºãèªã¿ãããšæã£ãŠãããããããã©ããŒããŠããã ãããšå¬ããã§ãã
ãã£ãšæ·±ãç¥ãããæ¹ãžïŒé¢é£èšäºïŒ
æ¥åŸ ãæžãããçµå¶è ã®æ°å€ãäžãããåŒãç®ã®é£ã¹æ¹ïŒåŸåã¯ã¡ã³ããŒéå®ïŒ
å®¶æãšã®é£äºãä»äºã®ä»ãåããæ®ãããŸãŸãé£ã¹æ¹ãã©ãå€ããããæ¥åŸ ãç¶ãçæŽ»ã§ãæåã®ææ¡ãç¶ããªãã£ãçç±ãšããã®åŸã«å€ããããšãæžããŠããã
ã¡ã³ããŒã·ãããDr.ãããã©ããã®ãç¥ãã
ã¡ã³ããŒã·ãããDr.ãããã©ãããéå¶ããŠããŸããXã»ç¡ænoteã§ã¯åºããªããããäžæ®µèžã¿èŸŒãã è©±ãæžããŠããŸãã
çµå¶è ã®äž»æ²»å»ãšããŠã倿¥ã§å®éã«è©±ããŠããå 容
è«æãèªã¿ãªããèªåã®äœã§è©Šãããå¹ããã»å¹ããªãã£ãèšé²
æ€æ»æ°å€ã®èªã¿æ¹ããµããªã»è¬ã®éžã³æ¹
ã¡ã³ããŒéå®ã®æ²ç€ºæ¿Q&A
æé¡1000åã§å šèšäºèªã¿æŸé¡ã§ããåããªãã£ããããè§£çŽã§ããŸããæ°ã«ãªã£ãæ¹ã¯ãèŠããŠã¿ãŠãã ããã
åèæç®
1) Leaf A, Rothschild JA, Sharpe TM, et al. International society of sports nutrition position stand: ketogenic diets. J Int Soc Sports Nutr. 2024;21(1):2368167. doi:10.1080/15502783.2024.2368167.
2) Musa-Veloso K, Likhodii SS, Cunnane SC. Breath acetone is a reliable indicator of ketosis in adults consuming ketogenic meals. Am J Clin Nutr. 2002;76(1):65-70. doi:10.1093/ajcn/76.1.65
3) Saslow LR, Daubenmier JJ, Moskowitz JT, et al. Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes. Nutr Diabetes. 2017;7(12):304. doi:10.1038/s41387-017-0006-9.
4) Gardner CD, Landry MJ, Perelman D, et al. Effect of a ketogenic diet versus Mediterranean diet on glycated hemoglobin in individuals with prediabetes and type 2 diabetes mellitus: The interventional Keto-Med randomized crossover trial. Am J Clin Nutr. 2022;116(3):640-652. doi:10.1093/ajcn/nqac154. èšæ£ïŒ2022;116(6):1904. doi:10.1093/ajcn/nqac279.
5) æ¥æ¬åè硬ååŠäŒ. åèç¡¬åæ§çŸæ£äºé²ã¬ã€ãã©ã€ã³2022幎ç. 2022.
6) Norwitz NG, Feldman D, Soto-Mota A, Kalayjian T, Ludwig DS. Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for a "Lean Mass Hyper-Responder" Phenotype. Curr Dev Nutr. 2022;6(1):nzab144. doi:10.1093/cdn/nzab144.
7) Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144.
8) Budoff M, Manubolu VS, Kinninger A, et al. Carbohydrate Restriction-Induced Elevations in LDL-Cholesterol and Atherosclerosis: The KETO Trial. JACC Adv. 2024;3(8):101109. doi:10.1016/j.jacadv.2024.101109.
9) Budoff MJ, Kinninger A, Manubolu VS, Norwitz NG, Feldman D, Soto-Mota A. The Impact of Sustained LDL-C Elevation on Plaque Changes: Primary Coronary plaque progression results from the Keto CTA Study. medRxiv. 2026幎1æ. doi:10.64898/2026.01.15.26343955. ãæ»èªåãã¬ããªã³ãã
10) American Diabetes Association. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetesâ2026. Diabetes Care. 2026;49(Suppl 1):S89-S131. doi:10.2337/dc26-S005
11) Choi YJ, Jeon SM, Shin S. Impact of a Ketogenic Diet on Metabolic Parameters in Patients with Obesity or Overweight and with or without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Nutrients. 2020;12(7):2005. doi:10.3390/nu12072005.
12) Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647-e663. doi:10.1016/j.jacl.2024.08.013.
â»æ¬èšäºã¯äžè¬çãªå¥åº·ã»å»åŠæ å ±ã®æäŸãç®çãšãããã®ã§ãããç¹å®ã®å人ã«å¯Ÿãã蚺æã»æ²»çã»å»åŠçå©èšãè¡ããã®ã§ã¯ãããŸãããå¥åº·äžã®æžå¿µãããå Žåã¯ãå¿ ãå»çæ©é¢ãå蚺ããŠãã ãããèšäºã®æ å ±ã«åºã¥ãè¡åã®çµæã«ã€ããŠã¯ãçè ã¯è²¬ä»»ãè² ããããŸãã